Beta-blockers and obstructive pulmonary diseases: Such an odd couple?;β-bloquants et obstruction bronchique: Un si mauvais ménage?

Revue Medicale Suisse

Volumn 2, Issue 50, 2006, Pages 285-288

  Grosgurin, Olivier ^a   Bria, Alexandre ^a   Gaspoz, Jean Michel ^a  

^a SERVICE DE MÉDECINE INTERNE GÉNÉRALE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE; CARVEDILOL; CELIPROLOL; ESMOLOL; LABETALOL; METOPROLOL; METOPROLOL TARTRATE; PINDOLOL; PRACTOLOL; PROPRANOLOL; VISKENE;

BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; HEART DISEASE; HUMAN; META ANALYSIS; MORTALITY; PATIENT SELECTION; PRESCRIPTION; REVIEW; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DRUG CONTRAINDICATION; FORCED EXPIRATORY VOLUME; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; BRONCHIAL SPASM; FORCED EXPIRATORY VOLUME; HEART DISEASES; HUMANS; PATIENT SELECTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 33645211931     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Zaid G, Beall GN. Bronchial response to beta-adrenergic blockade. N Engl J Med 1966;275:580-4.
2. McNeill RS. Effect of a beta-adrenergic-blocking agent, prapranolol, on asthmatics. Lancet 1964;2:1101-2.
3. Anderson EG, Calcraft B, Jariwalla AG, Al-Zaibak M. Persistent asthma after treatment with beta-blocking agents. Br J Dis Chest 1979;73:407-8.
4. Heller DA, Ahern FM, Kozak M. Changes in rates of beta-blocker use between 1994 and 1997 among elderly survivors of acute myocardial infarction. Am Heart J 2000;140:663-71.
5. Metoprolol in acute myocardial infarction. Patients and methods. The MIAMI Trial research Group. Am J Cardiol 1985;56:3G-9G.
6. National Heart, Lung, and Blood Institute. Beta-blocker heart attack trial study protocol. US Department of Health and Human Services, Public Health Service, National Institutes of Health, Washington DC, 1980.
7. Herlitz J, Holmberg S, Pennert K, et al. Göte borg Metoprolol Trial: Design, patients characteristics and conduct. Am J Cardiol 1984;53:3D-8D.
8. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981;2:823-7.
9. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J 1997;18:560-5.
10. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 1999;318: 1730-7.
11. Koch-Weser J. Beta-adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med 1984; 310:830-7.
12. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: A meta-analysis of placebo-controlled, randomized trials. Circulation 1998;98:1184-91.
13. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339:489-97.
14. Dart RA, Gollub S, Lazar J, et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest 2003;123:222-43.
15. Salpeter SS, Ormiston T, Salpeter E, et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2002.
16. Guidelines for the evaluation of impairment/disability in patients with asthma. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993;147:1056-61.
17. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective betablockers in patients with reactive airway disease: A meta-analysis. Ann Intern Med 2002;137:715-25.
18. Au DH, Bryson CL, Fan VS, et al. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med 2004;117:925-31.
19. Anavekar SN, Barter C, Adam WR, et al. A double-blind comparison of verapamil and labetalol in hypertensive patients with coexisting chronic obstructive airways disease. J Cardiovasc Pharmacol 1982;4:374S-7S.
20. Light RW, Chetty KG, Stansbury DW. Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with mild chronic obstructive pulmonary disease. Am J Med 1993;75:109-14.
21. Falliers CJ, Vrchota J, Blasucci DJ, et al. The effects of treatments with labetalol and hydrochlorothiazide on ventilatory function of asthmatic hypertensive patients with demonstrated bronchosensitivity to propranolol. J Clin Hypertens 1985;1:70-9.
22. George RB, Light RW, Hudson LD, et al. Comparison of the effects of labetalol and hydrochlorothiazide on the ventilatory function of hypertensive patients with asthma and propranolol sensitivity. Chest 1985;88:815-8.
23. Anavekar N, Doyle AE. Evaluation of verapamil in the treatment of hypertension. J Clin Hypertens 1986; 3:90S-9S.
24. van der Woude HJ, Zaagsma J, Postma DS. Detrimental effect of beta-blockers in COPD: A concern for nonseective beta-blockers. Chest 2005;127:818-24.